NanoBio Corporation and the University of Michigan’s, Michigan Nanotechnology Institute for Medicine and Biological Sciences will develop an intranasal vaccine for the treatment of hepatitis B (HBV). The effort is funded through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH).
According to James R. Baker, MD, CEO and founder of NanoBio. "This new intranasal vaccine would have great value as a treatment to reduce the risk of HBV associated liver diseases and deaths globally. The vaccine is also highly stable at room temperature enabling storage without refrigeration, a factor of great importance in the developing world.”
After successful completion of the preclinical studies funded by this STTR, NanoBio plans to conduct a FDA-approved Phase 1 clinical trial to evaluate safety, dose range, immunogenicity and preliminary efficacy against chronic HBV in humans with kidney failure.
- here's NanoBio's release
NanoBio inks $54.5M development deal with GSK
NanoBio tops up $22M round as it closes in on pact